Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 81-90 of 125 for

Edit search filters
  1. MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT)

    Scottsdale/Phoenix, AZ

  2. Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  3. A Study to Evaluate Exercise for Cancer Patients at Risk of Falling

    Rochester, MN

  4. Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

    Rochester, MN

  5. Therapeutic Drug Monitoring of Pembrolizumab and Nivolumab to Determine Dosages for Cancer Treatment

    Rochester, MN

  6. LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

  7. Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)

  8. Melanoma Relatlimab Nivolumab

    Jacksonville, FL, Rochester, MN

  9. Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

    Rochester, MN

  10. A Study to Evaluate the DermaSensor Tool on Skin Lesions Suggestive of Skin Cancer

    Rochester, MN

.

Mayo Clinic Footer